Camber Pharmaceuticals has received FDA approval for its generic Metformin HCl for oral administration, potentially generating additional revenue through increased generic competition to branded competitors. This approval, formalized on March 13, 2025, is expected to boost revenues by leveraging insured patient demand for cost-effective diabetes treatments.